CJC-1295 isn't available on pharmacy shelves in Karis or most other cities — it's a research compound available through a dedicated online market. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers more rigorous quality data than local retail ever could. Separating properly characterised CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Karis researchers need to know about finding, evaluating, and storing CJC-1295 for scientific research use.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Karis researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Evaluating CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before placing an order, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at very low concentrations. Community reputation in research forums is a complementary signal to COA verification — vendors with consistently positive reports over 12+ months have proved themselves through consistent results. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Karis
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. The most significant preventable safety hazard in CJC-1295 research is endotoxin contamination from poor sourcing — a confirmed endotoxin test result in the lot-matched COA is the specific protection against this risk. Protocol documentation — keeping clear records of compound, timing, and method — is a fundamental research principle that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
